Arjun Tarakad
A5085960308- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Autism Spectrum Disorder Research
- Biotechnology and Related Fields
- Neurogenetic and Muscular Disorders Research
- Nuclear Receptors and Signaling
- Botulinum Toxin and Related Neurological Disorders
- Genetic Neurodegenerative Diseases
- Lysosomal Storage Disorders Research
- Assistive Technology in Communication and Mobility
- Biomedical Ethics and Regulation
- Neuroscience and Neural Engineering
- Genomics and Rare Diseases
- Genetics and Neurodevelopmental Disorders
- Neurological diseases and metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Attention Deficit Hyperactivity Disorder
- BRCA gene mutations in cancer
- Functional Brain Connectivity Studies
- Dysphagia Assessment and Management
- RNA Research and Splicing
- Voice and Speech Disorders
- Clostridium difficile and Clostridium perfringens research
- Parkinson's Disease and Spinal Disorders
- Cancer Research and Treatment
Baylor College of Medicine
2016-2025
Baylor University
2020
Abstract Digital health technologies can provide continuous monitoring and objective, real-world measures of Parkinson’s disease (PD), but have primarily been evaluated in small, single-site studies. In this 12-month, multicenter observational study, we whether a smartwatch smartphone application could measure features early PD. 82 individuals with early, untreated PD 50 age-matched controls wore research-grade sensors, smartwatch, while performing standardized assessments the clinic. At...
<strong>Background:</strong> There is longstanding controversy surrounding the possible link between essential tremor (ET) and Parkinson's disease (PD). Inconsistent unreliable diagnostic criteria may in part account for some of difficulties defining relationship these two common movement disorders. <strong>Methods:</strong> References this systematic review were identified using PubMed with search terms ''essential tremor'' AND ''Parkinson's disease'' articles published English 1960...
As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations the provider. Continuous 24 h/day subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp) provides steady stimulation that can reduce symptom fluctuation. Our aim review initiation, optimization, maintenance LDp/CDp identify possible challenges, share potential mitigations. Review available clinical trial data...
Emerging technologies show promise for enhanced characterization of Parkinson's Disease (PD) motor manifestations. We evaluated quantitative mobility measures from a wearable device compared to the conventional assessment, Movement Disorders Society-Unified PD Rating Scale part III (motor MDS-UPDRS).We 176 subjects (mean age 65, 65% male, 66% H&Y stage 2) during routine clinic visits using MDS-UPDRS and 10-min protocol with body-fixed sensor (DynaPort MT, McRoberts BV), including 32-ft walk,...
Background: The efficacy of deep brain stimulation (DBS) therapy in Parkinson's disease (PD) patients is highly dependent on the precise localization target structures such as subthalamic nucleus (STN). Most commonly, microelectrode single unit activity (SUA) recordings are performed to refine target. This process heavily experience-based and can be technically challenging. Local field potentials (LFPs), representing a population neurons, obtained from same microelectrodes used for SUA allow...
Deep brain stimulation (DBS) for Parkinson disease (PD) is traditionally performed with awake intraoperative testing and/or microelectrode recording. Recently, however, the procedure has been increasingly under general anesthesia image-based verification. The authors sought to compare structural and functional networks engaged by asleep PD-DBS of subthalamic nucleus (STN) correlate them clinical outcomes.Levodopa equivalent daily dose (LEDD), pre- postoperative motor scores on Movement...
Background: Deep brain stimulation (DBS) is an effective treatment for Parkinson’s disease (PD), but its efficacy tied to the selection of optimal parameters individual patients. DBS programming often time consuming and burdensome patients, caregivers, clinicians. Our aim test whether Mobile Application PD (MAP DBS), a clinical decision support system, can improve programming.Methods: We conducted open-label, 1:1 randomized, controlled, multicenter trial comparing six months standard care...
Objective: To describe the outcome of globus pallidus interna (GPi) deep brain stimulation (DBS) in an adult patient with neurodegeneration iron accumulation (NBIA). Background: NBIA disorders are a heterogeneous group conditions dystonia being prominent feature many cases. Dystonia is often refractory to medication, and DBS has been attempted varying degrees success. Methods: We present case report 48 year old man onset NBIA who had initial presentation writer’s cramp at age 24,...